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The genome of hepatitis C virus (HCV) encodes two envelope glycoproteins (E1 and E2), which are thought to be
responsible for receptor binding and membrane fusion resulting in virus penetration. To investigate cell surface determinants
important for HCV infection, we used a recombinant vesicular stomatitis virus (VSV) in which the glycoprotein gene was
replaced with a reporter gene encoding green fluorescent protein (GFP) and produced HCV-VSV pseudotypes possessing
chimeric HCV E1 or E2 glycoproteins, either individually or together. The infectivity of the pseudotypes was determined by
quantifying the number of cells expressing the GFP reporter gene. Pseudotypes that contained both of the chimeric E1 and
E2 proteins exhibited 10–20 times higher infectivity on HepG2 cells than the viruses possessing either of the glycoproteins
individually. These results indicated that both E1 and E2 envelope proteins are required for maximal infection by HCV. The
infectivity of the pseudotype virus was not neutralized by anti-VSV polyclonal antibodies. Bovine lactoferrin specifically
inhibited the infection of the pseudotype virus. Treatment of HepG2 cells with Pronase, heparinase, and heparitinase but not
with phospholipase C and sodium periodate reduced the infectivity. Therefore, cell surface proteins and some glycosami-
noglycans play an important role in binding or entry of HCV into susceptible cells. The pseudotype VSV possessing the
chimeric HCV glycoproteins might offer an efficient tool for future research on cellular receptors for HCV and for the
development of prophylactics and therapeutics for hepatitis C. © 2001 Academic Press
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aINTRODUCTION
Hepatitis C virus (HCV) is the most important causative
agent of posttransfusion and sporadic non-A non-B hep-
atitis, infecting more than 200 million people worldwide
(Houghton, 1996). HCV infection becomes chronic in
most cases and may eventually result in hepatitis, liver
cirrhosis, and hepatocellular carcinoma (Alter et al.,
1992; Saito et al., 1990). This high percentage of chronic-
ity after HCV infection can be explained by (i) HCV
escape from the host protective immune responses by
mutating its amino acid sequences (Kato et al., 1993;
einer et al., 1992) or by (ii) the failure of HCV infection
o induce protective immune responses (Farci et al.,
992; Weiner et al., 1995). The HCV genome encodes two
envelope glycoproteins (E1 and E2), which are derived
from a precursor polyprotein after the polyprotein is pro-
cessed by signal peptidase. The two glycoproteins form
a heterodimer complex in the endoplasmic reticulum
(ER) (Deleersnyder et al., 1997; Dubuisson et al., 1994,
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earch Institute for Microbial Diseases, Osaka University, Osaka 565-t
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263000; Dubuisson, 2000; Grakoui et al., 1993; Matsuura et
l., 1994; Ralston et al., 1993; Selby et al., 1994), which is
the site where virus budding is thought to occur.
Although some cell lines have been shown to support
HCV replication, which was only detectable by nested
PCR (Ito et al., 1996; Mizutani et al., 1996; Shimizu et al.,
992), the lack of a conventional cell culture system for
CV has greatly limited studies of the infection mecha-
isms of HCV and the assessment of protective antibody
esponses to HCV. Rosa and colleagues (1996) reported
hat a truncated form of the HCV E2 protein (type 1a) can
ind to Molt-4 cells and that the interaction could be
nhibited by antibody. This assay was named the neu-
ralization of binding (NOB). We have shown that the
ppearance and maintenance of high titers of NOB an-
ibodies are accompanied by clinical resolution of liver
isease and virus clearance (Ishii et al., 1998). More
ecently it was reported that human CD81 (hCD81) could
e bound by a truncated, soluble form of the E2 protein
Pileri et al., 1998), suggesting that hCD81 may act as a
eceptor for HCV on the cell surface; however, it is not
nown whether hCD81 serves as a functional receptor
nd can lead to a productive HCV infection.
One of the ways to overcome the lack of a conven-
ional cell culture system for HCV is to generate
seudotype viruses that have HCV envelope proteins on
0042-6822/01 $35.00
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264 MATSUURA ET AL.the surface of another virus (Rubin, 1965). Vesicular sto-
matitis virus (VSV) can be efficiently propagated in many
animal cells and readily forms pseudotypes with the
envelope proteins from many different viruses. Recently,
systems to recover recombinant Rhabdoviruses, specif-
ically rabies virus and VSV, from cDNA clones have
become available (Lawson et al., 1995; Schnell et al.,
1994; Whelan et al., 1995). In addition, it has been dem-
nstrated that foreign glycoproteins can be incorporated
fficiently into recombinant rhabdovirus envelopes (Me-
atsion et al., 1996; Schnell et al., 1996). One approach
that has been used to study the entry mechanism of a
number of different viruses that are either difficult to
grow or that require high-level containment facilities uti-
lizes a novel recombinant VSV (VSVDG*) that encodes
the green fluorescent protein (GFP) gene instead of the
glycoprotein (G) gene. Transient expression of foreign
envelope glycoproteins in VSVDG*-infected cells re-
sulted in the release of infectious pseudotype viruses
which were subsequently used to examine the cell entry
properties conferred by the foreign viral proteins (Okuma
et al., 2001; Takada et al., 1997; Tatsuo et al., 2000).
To examine the role of the two HCV envelope proteins
in cell infection, we produced pseudotype VSVs that had
modified HCV envelope proteins, either individually or
together, instead of the VSV G glycoprotein. Both of the
HCV E1 and E2 proteins have C-terminal retention sig-
nals and these proteins are normally retained in the ER
(Cocquerel et al., 1998, 1999). To incorporate the HCV
envelope proteins into VSV virions, the envelope proteins
must be expressed on the cell surface. Therefore, chi-
meric proteins containing the signal sequence, trans-
membrane domain, and cytoplasmic tail of VSV G glyco-
FIG. 1. Chimeric HCV envelope genes used in this study. The gene
equences of HCV E1 and E2 proteins are shown in the middle. V340V
ossess the transmembrane and cytoplasmic tail of VSV-G protein. V38
he signal sequence of VSV-G protein. Gray bars are the putative tranprotein and the ectodomain of HCV E1 or E2 protein were
generated (Takikawa et al., 2000). Incorporation of both
p
3of the chimeric E1 and E2 proteins into virions was
required to confer maximal infectivity on the pseudotype
virions. Among the cell lines examined, HepG2 cells
exhibited the highest susceptibility to the pseudotype
VSV. Chemical modification analyses suggest that pro-
tein molecules and glycosaminoglycans on HepG2 cells
may play an important role in the infection of HCV.
RESULTS
Characterization of CHO cell lines expressing the
chimeric HCV envelope proteins
To generate pseudotype VSVs bearing HCV envelope
proteins, it was necessary to express both E1 and E2 on
the cell surface, since VSV assembles and buds from the
plasma membrane. CHO cell lines constitutively ex-
pressing chimeric E1 and E2 proteins, either individually
(CHOE1 and CHOE2) or together (CHOE1E2), were es-
tablished using chimeric cDNA constructs encoding the
ectodomains of E1 or E2 joined to the transmembrane
and cytoplasmic domains of VSV-G protein (Takikawa et
al., 2000) (Fig. 1). To confirm that the chimeric proteins
were expressed on the cell surface, the CHO cell lines
were analyzed by flow cytometry using monoclonal an-
tibodies against E1 or E2 protein. The appropriate chi-
meric protein was detected on the cell surface of each of
the E1 or E2 CHO cell lines, and both proteins were
present on the CHOE1E2 cell line (Fig. 2A). To examine
the processing of the chimeric E1 and E2 proteins, the
CHOE1E2 cell line was pulse labeled for 15 min with
[35S]methionine and cysteine and chased for 4 h and the
roteins were immunoprecipitated by E1- or E2-specific
onoclonal antibodies (Fig. 2B, left). The chimeric E1
ure of HCV is shown at the top. Hydrophobic profiles of amino acid
11V are chimeric proteins, which have deletions in C-terminus and that
809 are full-length cDNA clones. Black bars in the N-terminus indicate
rane regions of the HCV envelope proteins.struct
and V7rotein migrated as a doublet with molecular weights of
4 and 36 kDa soon after labeling, which then shifted
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265PSEUDOTYPE VSVs POSSESSING HCV ENVELOPE PROTEINSinto diffuse bands of 50–60 kDa after 2 h chase in both
the CHOE1 (not shown) and the CHOE1E2 cells. In con-
trast, the size of the chimeric E2 protein in both the
CHOE2 (not shown) and the CHOE1E2 lines was 60 kDa,
and this did not change during the chase period. Under
the conditions used for immunoprecipitation, we could
not detect any heterodimer formation between the chi-
meric E1 and E2 proteins in the CHOE1E2 cell line. This
FIG. 2. (A) Cell surface expression of chimeric HCV envelope protein
2 monoclonal antibody and FITC-conjugated goat anti-mouse IgG and
y the shift of the solid histogram to the right from the control histogra
ntibody only. Axes: FL1-Height, fluorescence intensity; Counts, numbe
as labeled for 15 min with Tran 35S-label and chased for 2 and 4 h. T
ntibodies. Right, CHOE1E2 cell line was labeled for 15 min with Tran
ith anti-E1 monoclonal antibody and the immunoprecipitates were di
nvelope proteins are indicated by the arrows. Molecular weight markmight be a consequence of weak ectodomain interac-
tions of the chimeric HCV envelope proteins that are notmaintained in the detergents used for lysis. To examine
the oligosaccharides on the chimeric E1 protein, the
CHOE1E2 cell line was pulse labeled with radioactive
methionine and cysteine and chased for 6 h, and the
chimeric protein was immunoprecipitated with an anti-E1
monoclonal antibody. The immunoprecipitate was di-
gested with endo-b-N-acetylglucosaminidase H (Endo
H) or peptide-N-glycosidase F (PNGase F) (Fig. 2B, right).
e CHO cell lines. CHO cell lines were immunostained with anti-E1 or
ed by flow cytometry. The level of cell surface expression is indicated
n, dashed line) in which cells were stained with the FITC-conjugated
lls. (B) Left, pulse-chase analyses of CHO cell line. CHOE1E2 cell line
lysates were immunoprecipitated with either the E1 or E2 monoclonal
l and chased for 3 and 6 h. The cell lysates were immunoprecipitated
with Endo H (H) or PNGase F (F). The positions of the chimeric HCV
shown on the right.s on th
analyz
m (ope
r of ce
he cell
35S-labeAfter a 6-h chase, the chimeric E1 protein was resistant
to Endo H treatment, suggesting that 60-kDa species
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266 MATSUURA ET AL.resulted from the addition of complex-type carbohy-
drates. In contrast, the E2 protein did not appear to
acquire complex oligosaccharides and migrated at the
same molecular weight from the time of synthesis until at
least 4-h postchase.
Although the exact molecular characteristics of HCV
envelope proteins in the virion are not known yet, the
carbohydrates of the envelope proteins on the virions are
probably processed into complex type during transport
to the cell surface, even if the virions bud into the ER
lumen.
Production of pseudotype VSVs
To determine whether the chimeric proteins could be
incorporated into VSV particles, we infected the two CHO
cell lines expressing each of the chimeric envelope pro-
teins individually, or the cell line expressing E1 and E2
together, with VSVDG*-G, which consists of DG* virions
complemented in trans with VSV-G protein (Fig. 3A). After
16 h the infected cell supernatants were collected and
the pseudotyped viruses were purified by centrifugation
through sucrose density gradients and analyzed by im-
munoblotting (Fig. 3B). As controls, VSVDG*-G and
VSVDG* were produced by infecting CHO cells tran-
siently expressing VSV-G protein, or the parental CHO
cells, with VSVDG*-G, respectively. The VSV structural
proteins N, P, and M (matrix protein) were present in all
of the purified virions. VSV-G protein was only detected in
VSVDG*-G (lane 1) but not in VSVDG* negative control
(lane 2) nor in the HCV pseudotype viruses (lanes 3–5).
Virions produced in cells expressing the chimeric HCV
envelope proteins contained either E1 or E2 (lanes 3 and
4) or both of the chimeric envelope proteins (lane 5),
indicating that both proteins were competent for assem-
bly into VSV particles.
Infectivity of HCV pseudotype VSVs
To examine whether the pseudotype viruses possess-
ing HCV envelope proteins could rescue the infectivity of
VSV lacking G protein, we incubated HepG2 cells with
supernatants containing the pseudotype viruses. The
infection was then determined by examining the cells for
GFP expression using fluorescence microscopy (Fig. 4).
The titer of VSV-E1E2 was about 10–20 times higher
(;4 3 105 IU/ml) than that of VSV-E1, VSV-E2, or VSVDG*
(,2 3 104 IU/ml), indicating that both of the chimeric
roteins were required for maximal infectivity. We next
xamined the susceptibility of various cell lines to VSV-
1E2, VSVDG*, and VSVDG*-G (Table 1). HepG2 cells
xhibited the highest susceptibility followed by COS7,
V-1, 293T, and Huh7 cells. The other cell lines, includinghe NIH3T3 cell line expressing hCD81, showed no de-
ectable susceptibility to VSV-E1E2.eutralization of the pseudotype virus
To determine whether the infectivity of VSV-E1E2 was
CV specific, we examined whether the pseudotypes
ould be neutralized by a polyclonal antibody against
SV. As shown in Fig. 5, the anti-VSV antibody completely
eutralized VSVDG*-G, whereas no neutralization was
bserved with the VSV-E1E2 pseudotypes. These results
uggest that infectivity of the VSV-E1E2 was not due to
esidual inoculum nor due to adventitious incorporation
f VSV-G protein into the pseudotype virions. However,
o neutralization was observed with the sera from a
himpanzee immunized with HCV E1 and E2 proteins,
or with sera from patients possessing neutralization of
inding antibodies, nor with mouse monoclonal antibod-
es recognizing HCV envelope proteins.
ffects of bovine lactoferrin and Suramin on
seudotype infection
Previously it was shown that bovine lactoferrin, a milk
rotein belonging to the iron transporter family, pre-
ented HCV infection in human hepatocytes (Ikeda et al.,
988). In another study, Suramin, which is a polysulpho-
ate pharmaceutical, blocked binding of HCV to human
epatocytes (Garson et al., 1999). To examine the effect
f bovine lactoferrin or Suramin on the infection of the
seudotype virus, VSV-E1E2 and VSVDG*-G were prein-
ubated with the compounds and then the inoculum was
dded to HepG2 cells (Fig. 6). Pretreatment with bovine
actoferrin reduced the infectivity of VSV-E1E2 in a dose-
ependent manner, whereas no effect was observed on
he infectivity of VSVDG*-G. Similarly, preincubation with
uramin reduced the infectivity of VSV-E1E2, but the
nfectivity of VSVDG*-G was also inhibited at the higher
oncentrations.
ffects of chemical modifications of HepG2 cells on
nfectivity of the pseudotype VSV
To obtain information on the biological characteristics
f cellular receptors for HCV, we examined the infectivity
f the pseudotype VSV-E1E2 on chemically modified
epG2 cells. HepG2 cells were treated with various
oncentrations of protease, sodium periodate, or phos-
holipase C and then the treated cells were infected with
.5 3 103 IU of the VSV-E1E2 or VSVDG*-G. The effects of
the chemical modifications on infectivity were evaluated
by counting the number of GFP-positive (infected) cells
using fluorescence microscopy (Fig. 7A). When HepG2
cells were treated with Pronase, the infectivity of the
VSV-E1E2 was markedly reduced compared to the infec-
tivity of VSVDG*-G. However, treatment with phospho-
lipase C or sodium periodate did not inhibit the infection
with either of the viruses. These results suggest that
protein molecule(s) on cell surface plays an important
role in infection of VSV-E1E2.
OE1, CH
or an
ectively
267PSEUDOTYPE VSVs POSSESSING HCV ENVELOPE PROTEINSGlycosaminoglycans (GAGs) are unbranched polysac-
charides ubiquitously present on cell surfaces and have
been shown to be important in the cell surface binding of
a number of bacteria, parasites, and viruses (Rostand
and Esko, 1997). In dengue virus, for example, a highly
FIG. 3. (A) Generation of pseudotype VSVs in CHO cell lines constitu
of the pseudotype VSVs. (B) Western blot analyses of the pseudotype V
of the pseudotype VSVs is shown at the top. (1) VSVDG*-G is complem
of the VSV G gene. (2) VSVDG* has no envelope protein and was prepa
and (5) VSV-E1E2 were recovered by inoculation of VSVDG*-G into CH
with Western blots using an anti-VSV polyclonal antibody, an anti-E1
nucleocapsid protein, phosphoprotein, and matrix protein of VSV, respsulfated heparan sulfate has been shown to effectively
prevent the infection of target cells (Chen et al., 1997). Toexamine the role of GAGs on the infectivity of the
pseudotype virus, HepG2 cells were treated with several
GAG lyases. Treatment of HepG2 cells with heparinase
or heparitinase reduced the infectivity of the VSV-E1E2,
whereas no reduction in infectivity was observed after
expressing the chimeric HCV envelope proteins and infectivity assays
ossessing HCV chimeric envelope proteins. Schematic representation
ith the VSV G protein, but the genome contains the GFP gene instead
he parental CHO cells infected with VSVDG*-G. (3) VSV-E1, (4) VSV-E2,
OE2, and CHOE1E2, respectively. The purified virions were analyzed
anti-E2 monoclonal antibody. G, N, P, and M are the glycoprotein,
.tively
SVs p
ented w
red in tthe cells were treated with keratanase, hyaluronidase, or
chondroitinase (Fig. 7B).
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268 MATSUURA ET AL.DISCUSSION
A high risk of chronicity is the major concern of HCV
nfection. Chronic infection of HCV often leads to liver
TABLE 1
Infectivities of Pseudotype VSVs for Different Cell Lines
Species Cell line
Infectious units/ml (3103)
VSV-E1E2 VSVDG*-G VSVDG*
Human HepG2 314.0 347.0 15.0
Huh7 29.4 13.9 8.0
FLC4 2.2 472.0 0
293T 61.0 497.0 7.7
HeLa 0.3 26.5 0
Monkey COS7 121.8 10.8 9.0
CV-1 67.0 173.0 14.0
MA104 4.2 45.1 0
Swine CPK 2.2 194.7 0
Bovine MDBK 0 14.3 0
Canine MDCK 2.0 1.2 0
Hamster CHO 0 32.0 0
BHK21 0 386.4 0
Rat BRL3A 0 1.2 0
Murine NMuLi 0 12.0 0
NIH3T3 0 28.8 0
NIH3T3-hCD81 0 45.5 0
Note. VSVDG-E1E2, VSVDG* and VSVDG*-G were prepared by in-
fecting the CHO cell line expressing both of the chimeric E1 and E2
proteins, normal CHO cells and those transiently expressing VSV-G
protein with VSVDG*-G, respectively. To adjust the infectious titer,
VSVDG*-G was diluted 1023 with DMEM containing 10% FBS. Various
ell lines were infected with the pseudotype VSVs from the same batch.
FIG. 4. Infectivity of the pseudotype VSVs on HepG2 cells. The pseudotype
SVs produced in the CHO cell lines constitutively expressing the chimeric
CV envelope proteins were added to HepG2 cells and infectivity of the
seudotype viruses was determined by quantifying the number of GFP
xpressing cells. The results shown are from three independent as-
ays, with the error bars representing the standard deviation (SD).he data are representative results from experiments repeated with
hree batches of viruses.
v
eirrhosis and hepatocellular carcinoma. The elimination
f HCV from chronic hepatitis patients is of utmost im-
ortance. However, the complete removal of HCV has not
een accomplished even at the experimental level. Fur-
hermore, the study of the infection mechanism of HCV
as been hampered by the lack of an efficient cell cul-
ure-based infection-neutralization assay.
To overcome these problems, we produced
seudotyped VSVs possessing chimeric HCV glycopro-
eins and then examined the infectivities of the
seudotypes by a simple fluorescence assay based on
he expression of GFP from the pseudotyped viral ge-
ome. To assess the neutralization activity of HCV-spe-
ific antibodies, a NOB assay has been developed which
easures the inhibition of binding of the purified E2
rotein to hCD81 (Ishii et al., 1998; Rosa et al., 1996).
However, the correlation between the NOB activity and
true virus neutralization activity remains to be proven. We
examined the sera from the immunized chimpanzees as
well as the sera from patients possessing NOB antibod-
ies; however, none of these had neutralization activity
against the pseudotyped VSVs. These results suggest
that some antibodies, which can inhibit E2 binding, may
not prevent HCV infection. The use of the pseudotype
virus allows the examination of multiple steps of infec-
tion, including binding both to the host receptor and to
the membrane fusion. It therefore might be more relevant
to examine the native functions of HCV envelope pro-
teins using pseudotype VSV bearing both E1 and E2
proteins rather than the simple binding assay of the
purified E2 protein to hCD81. Although hCD81 was sug-
FIG. 5. Neutralization of pseudotype VSVs. A polyclonal antibody
against VSV was serially diluted and incubated with 2.5 3 103 IU of
SV-E1E2 or VSVDG*-G for 30 min at 37°C. The amount of infectious
irus remaining was quantified by determining the number of GFP
xpressing cells.
2
g
a
t
c
i
m
t
r
1
b
t
e
t
p
w
r
1
E
c then a
p penden
269PSEUDOTYPE VSVs POSSESSING HCV ENVELOPE PROTEINSgested to be the binding receptor for the E2 protein of
HCV (Pileri et al., 1998), a NIH3T3 mouse cell line con-
stitutively expressing hCD81 did not exhibit a higher
susceptibility of infection for the pseudotyped virus than
the parental NIH3T3 cell line. In addition, we recently
established an HCV-specific cell fusion assay based on
the activation of a reporter gene (Takikawa et al., 2000).
The fusion assay utilizes the same CHO cell lines ex-
pressing the chimeric HCV envelope proteins as was
used in this study. We found that expression of hCD81 in
the same NIH3T3 cell line did not elicit cell–cell fusion
(Takikawa et al., 2000), even though the truncated E2
protein from the type 1b HCV clone used in this study
efficiently bound to the NIH3T3 cell line expressing
hCD81 (data not shown). Although hCD81 is expressed
on the surface of many human cell lines (Levy et al.,
1998), expression levels of hCD81 on the HepG2 cell line
are much lower than that of other human cell lines
examined (Flint et al., 1999). Nonetheless, HepG2 cells
showed the highest susceptibility to the pseudotyped
VSV as well as the most cell–cell fusion (Takikawa et al.,
2000). These results suggest that expression of hCD81
alone is not sufficient for infection of HCV and that
another molecule or cofactor might be required. In the
case of HepG2 cells, HCV infection may occur in an
hCD81-independent manner.
We found that incorporation of both of the chimeric E1
and E2 proteins into virions was essential for maximal
infectivity of the pseudotypes. This finding is different
from the data reported by Ray and colleagues in which
pseudotyped VSVs possessing either a chimeric E1-G or
a chimeric E2-G envelope protein individually was suffi-
cient for virus infectivity on various mammalian cells
(Lagging et al., 1998; Meyer et al., 2000). The results by
FIG. 6. Effect of bovine lactoferrin and Suramin on the infectivity
oncentrations of bovine lactoferrin or Suramin at 37°C for 60 min and
ositive cells was determined. The results shown are from three indeRay et al. are also inconsistent with our previous studies
in which expression of the both of the chimeric HCV
t
oenvelope proteins was essential for maximal cell–cell
fusion activity (Takikawa et al., 2000). Furthermore, our
E1E2 pseudotyped virus showed no infectivity on BHK
cells, whereas the pseudotype viruses generated by
Ray’s group exhibited the highest infectivity on BHK cells.
Although we do not know the reasons for these contra-
dictory results, the differences might be attributable to
the system used to produce the pseudotype VSV. We
employed a system in which foreign proteins expressed
in trans were incorporated into a recombinant VSV that
lacked the glycoprotein gene. This system was used
previously for the production of infectious pseudotype
VSVs possessing the Ebola virus glycoprotein (Takada et
al., 1997), measles virus glycoproteins (Tatsuo et al.,
000), and human T-cell leukemia virus type 1 envelope
lycoprotein (Okuma et al., 2001). On the other hand, Ray
nd colleagues used a temperature-sensitive VSV mu-
ant (ts045) for production of the pseudotype VSVs in
ombination with a recombinant vaccinia virus express-
ng T7 RNA polymerase. Alternatively, the differences
ay be due to the type of HCV envelope protein used or
he way that the chimeric proteins were constructed.
The envelope proteins of HCV contain signals that
etain these proteins in the ER (Cocquerel et al., 1998,
999). The maturation and budding site of HCV is also
elieved to be the ER. In this study, we used stably
ransformed CHO cell lines expressing chimeric HCV
nvelope proteins instead of a transient expression sys-
em to produce the pseudotype VSVs. The size of the E1
rotein expressed on the cell surface of the CHO cells
as larger (60 kDa) than those expressed in the ER, as
eported previously (30–35 kDa) (Fournillier-Jacob et al.,
996; Meunier et al., 1999), and the glycans found on the
1 chimera were processed to complex, endo H resis-
dotype VSVs. VSV-E1E2 or VSVDG*-G were pretreated with various
dded to HepG2 cells. After 16 h of incubation, the number of the GFP
t assays, with the error bars representing SD.of pseuant forms. Although the exact molecular characteristics
f HCV envelope proteins in the virion are not known yet,
f the VS
three
270 MATSUURA ET AL.the carbohydrates of the envelope proteins on the virions
are probably processed into complex type during trans-
port to the cell surface, even if the virions bud into the ER
lumen. When we produced pseudotype VSVs using a
transient expression system with 293T cells, the infec-
tious titers were lower than those obtained from the CHO
cell lines (data not shown). Whether this difference is
FIG. 7. Effect of chemical modification of HepG2 cells on infectivity o
of Pronase, sodium periodate, or phospholipase C. (B) HepG2 cells
chondroitinase ABC. The treated cells were infected with 2.5 3 103 IU o
of the GFP positive cells was determined. The results shown are fromdue to the amount of E1 and E2 expressed on the cell
surface or due to differences in glycosylation is notknown, but the possibility that the glycosylation state of
E1 might be important for infection is intriguing. Several
smaller forms of the chimeric E2 protein were detected in
the VSV-E2 particles in comparison to that found in VSV-
E1E2, suggesting that the chimeric E2 protein was some-
what unstable and susceptible to proteolysis. Although
we could not detect an interaction between the chimeric
otype VSVs. (A) HepG2 cells were treated with various concentrations
treated with heparinase, heparitinase, hyaluronidase, keratanase, or
V-E1E2 or VSVDG*-G, incubated at 37°C for 16 h and then the number
independent assays, with the error bars representing SD.f pseud
wereE1 and E2 proteins, coexpression of the two proteins
may contribute to their stability.
271PSEUDOTYPE VSVs POSSESSING HCV ENVELOPE PROTEINSThe effects of chemical modification of HepG2 cells on
the infectivity of the pseudotype virus suggest that pro-
tein molecules and GAGs on the cell surface play an
important role in the binding and/or entry of the
pseudotype VSV particles. These cell surface compo-
nents presumably serve as cellular receptors or cofac-
tors for the virus. The role of GAGs is to bind a diverse
group of growth factors, chemokines, enzymes, and ma-
trix components. Many viruses, including herpesviruses
(Lycke et al., 1991; WuDunn and Spea, 1989), human
immunodeficiency virus-1 (HIV-1) (Mondor et al., 1998;
Patel et al., 1993; Roderiquez et al., 1995), picornaviruses
(Jackson et al., 1996), and alphaviruses (Byrnes and Grif-
fin, 1998; Klimstra et al., 1998), utilize GAGs to mediate
attachment and infection of target cells. Heparin binding
proteins are known to interact with heparin via electro-
static interactions generated between the negatively
charged sulfate groups on heparin and the positively
charged amino acids within the protein (Cardin and
Weintraub, 1989; Flynn and Ryan, 1995; Trybala et al.,
1996). In dengue virus, both a highly sulfated heparan
sulfate and a polysulphonate pharmaceutical, Suramin,
were shown to effectively prevent infection of target cells
(Chen et al., 1997). HCV envelope proteins were pre-
dicted to possess a heparin-binding motif (Chen et al.,
1997) and Suramin was shown to be capable of blocking
HCV binding to HepG2 cells by using a PCR assay
(Garson et al., 1999). However, in this study the effect of
Suramin on the infection of pseudotype VSVs was not
specific at high concentrations of this compound. Fur-
thermore, it should be noted that additional receptors
besides GAGs are involved in binding and entry of many
of these viruses. The situation has been most carefully
studied with HSV-1, where binding to heparan sulfate is
followed by binding to a more specific protein receptor
(Montgomery et al., 1996). Sindbis virus was shown to
replicate on GAG-deficient pgsA-745 CHO cells and the
presence of other receptors was suggested (Byrnes and
Griffin, 1998). Although the nature of these additional
receptors is not completely clear, it has previously been
found that treating cells with either proteases or phos-
pholipases decreases binding of Sindbis virus (Ubol and
Griffin, 1991).
Although chimpanzees immunized with E1 and E2
proteins were protected from viral challenge with the
homologous HCV strain (Choo et al., 1994), earlier stud-
ies had shown that chimpanzees can be readily rein-
fected, even with homologous strains of HCV (Farci et al.,
1992). Therefore, it is believed that cross neutralization
between different genotypes will be difficult to achieve
(Lemon and Thomas, 1997). Based on these observa-
tions, the serum of a chimpanzee immunized with the E1
and E2 proteins of HCV type 1a may not be able to
neutralize the pseudotyped virus produced in this study,
which possessed the type 1b envelope proteins. In the
case of HIV-1 vaccines, it had been widely accepted thatmultiple envelope protein immunogens might be needed
to span the range of HIV sequence diversity (Wrin et al.,
1995). However, LaCasse et al. recently demonstrated
that epitopes with superior immunogenicity are exposed
when HIV-1 begins to fuse with host cell membranes.
These authors reported that HIV-1 gp120-gp41-CD4 fu-
sion complexes elicited antibodies in transgenic mice
which were capable of neutralizing a broad range of
primary isolates of HIV (LaCasse et al., 1999). Extending
these findings to HCV, it might be possible that fusion
intermediates are the critical targets for HCV neutralizing
antibodies, and that these antibodies would be effective
for a broad range of HCV genotypes.
It has been demonstrated that human as well as bo-
vine lactoferrin binds HCV envelope proteins and the
regions responsible for specific interactions between
HCV envelope proteins and lactoferrin have been deter-
mined (Yi et al., 1997). Furthermore, Ikeda et al. demon-
strated that bovine lactoferrin prevented HCV infection in
human cultured cells (Ikeda et al., 1988, 2000). In this
study, we found that bovine lactoferrin exhibited a spe-
cific and dose-dependent inhibition of VSV-E1E2 infec-
tion, but had no effect on cell infection by VSVDG*-G.
This specific inhibition of VSV-E1E2 infection by bovine
lactoferrin suggests that the infection of HepG2 cells by
the VSV-E1E2 pseudotypes is likely to be similar to the
infection of cells by native HCV virions.
In summary, we have established a system for the
production of VSV pseudotypes possessing modified
HCV envelope proteins using a CHO cell line constitu-
tively expressing both of the chimeric HCV envelope
proteins. In addition to providing information on the na-
ture of cellular receptors used by HCV, the VSV-E1E2
pseudotypes also offer a unique tool to identify potential
antiviral agents specific for HCV, as well as a reagent
that could be used to analyze HCV-specific neutralizing
antibodies or to develop a new class of HCV vaccines.
MATERIALS AND METHODS
Plasmids
The cDNA for the VSV (Indiana serotype) G protein
was excised from pGL-1 (Rose and Bergmann, 1982) and
cloned into a mammalian expression plasmid pCAGGS
(Niwa et al., 1991) under the CAG promoter. The resulting
plasmid was designated as pCAG-VSVG. Construction of
expression plasmids encoding chimeric E1 (pCAV340V)
and E2 protein (pCAV711V) was described in detail
(Takikawa et al., 2000). The chimeric E1 and E2 con-
structs consisted of the ectodomains of E1 or E2 protein
of type 1b HCV cDNA clone (NIH-J1) (Aizaki et al., 1998)
and the N-terminal signal sequences, transmembrane,
and cytoplasmic domains of VSV G protein, as shown in
Fig. 1. The chimeric E1 and E2 cDNA clones were ex-
cised by EcoRI digestion from the pCAV340V and
pCAV711V and cloned into pEF-puro and pEF-neo
s
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ion plasmids were designated as pEF-puro E1 and
EF-neo E2.
ells
CHO cells were transfected with either or both of the
EF-puro E1 and pEF-neo E2 by electroporation (300 V,
60 mF, Bio-Rad Gene Pulser, Bio-Rad), selected with
uromycin (Sigma, St. Louis, MO, 10 mg/ml), and/or ge-
neticin (1 mg/ml; Gibco BRL, Gaithersburg, MD) and
stable cell lines were obtained. CHOE1, CHOE2, and
CHOE1E2 express the chimeric E1, or E2, or both of the
proteins, respectively. Various mammalian cell lines
were used to examine their susceptibility to infection by
the pseudotype VSVs. These included human cell lines
(HepG2, FLC4, Huh7, HeLa, 293T), monkey kidney cell
lines (CV-1, COS7, and MA104), as well as cell lines
derived from other species, including CPK, MDBK,
MDCK, BHK21, CHO, BRL3A (rat liver cell), NMuLi (mouse
liver cell), NIH3T3, and NIH3T3hCD81, which expresses
hCD81. These cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) (GIBCO Laboratories, Grand
Island, NY) containing 2 mmol of L-glutamine, penicillin
50 IU/ml), streptomycin (50 mg/ml), and 10% fetal bovine
serum (FBS) or in the media recommended by the Amer-
ican Type Culture Collection (ATCC). HepG2 cells were
purchased from the Dainippon Pharmaceutical Co., Ltd.,
Osaka, Japan. Huh7 was a gift from the Japanese Cancer
Research Resources Bank-Cell, Tokyo. BRL3A and
NMuLi were purchased from the ATCC. NIH3T3hCD81
and NIH3T3 were kindly provided by Dr. S. Abrignani,
IRIS, Chiron, Siena Italy.
Characterization of the chimeric HCV proteins in CHO
cell lines
Expression of the chimeric HCV proteins was analyzed
by flow cytometry. Cells were detached, washed with
DMEM containing 2% FBS, and incubated with anti-E1
and anti-E2 monoclonal antibodies raised against par-
tially purified recombinant E1 and E2 proteins expressed
by recombinant baculoviruses (Matsuura et al., 1994) for
30 min on ice. After washing, cells were incubated with
fluorescein isothiocyanate (FITC)-conjugated goat anti-
mouse IgG (TAGO, Burlingame, CA) diluted to 1:100 in
phosphate-buffered saline (PBS) for 30 min on ice. After
washing with PBS, the cells were analyzed by a FACScan
flow cytometer (Becton–Dickinson, San Jose, CA). To
examine the processing of the chimeric proteins in the
CHO cell lines, cells were labeled with 20 mCi of Tran
35S-label (ICN, Irvine, CA) for 15 min after 2 h of starvation
ith medium deficient in FBS, methionine, and cysteine.
he medium was then replaced with normal growth me-
ium, and the radioactively labeled cells were chased for
, 2, and 4 h, washed twice with PBS, and dissolved in
00 ml of TNE buffer (10 mM Tris–HCl, pH 7.8, 150 mMaCl, 1 mM EDTA, 1% NP-40, 10 mg of aprotinin per ml).
ell lysates (100 ml) were suspended in 900 ml of TNE
buffer and incubated with 0.5 mg of the anti-E1 or E2
monoclonal antibody and 20 ml of Protein A Sepharose
Pharmacia, Tokyo) [50% suspension (v/v) in TNE buffer]
or 1 h at 4°C with rotating. After centrifugation at 8000 g
or 10 s at 4°C, the pellets were washed twice with TNE
uffer. Immunoprecipitated proteins were eluted from
rotein A Sepharose in 50 ml of 0.5% SDS and 50 mM
2-mercaptoethanol by boiling for 2 min. The immunopre-
cipitates were analyzed by SDS–PAGE. To examine the
type of oligosaccharides present on the chimeric E1
envelope protein, the CHOE1E2 cell line was pulse-
chase labeled and immunoprecipitated with anti-E1
monoclonal antibody. The immunoprecipitates were di-
gested with Endo H or PNGase F following a protocol
provided by the manufacturer and the proteins were
analyzed by SDS–PAGE.
Production of pseudotype VSVs possessing chimeric
HCV envelope proteins
A recombinant VSVDG*-G was generated by reverse
genetics as described previously (Takada et al., 1997).
Briefly, BHK cells were infected with a recombinant vac-
cinia virus expressing T7 RNA polymerase (vTF7-3) and
then transfected with a T7 expression plasmid encoding
a full-length cDNA clone of a recombinant VSV genome,
in which the G protein coding region was replaced with
the GFP gene (DG*), together with plasmids expressing
the VSV nucleocapsid protein (N), phosphoprotein (P),
polymerase protein (L), and glycoprotein (G). After re-
moval of the vaccinia virus by filtering, the DG* virus was
passaged on cells transiently expressing G protein only.
The VSV-G complemented virus is denoted VSVDG*-G.
To produce DG* particles containing the chimeric HCV
envelope proteins, the CHO cell lines were infected with
VSVDG*-G at a multiplicity of infection of 5. The virus was
adsorbed for 1 h at 37°C and extensively washed three
times with DMEM without FBS. After 16 h of incubation at
37°C, culture supernatants were collected and centri-
fuged to remove cell debris. Pseudotyped VSVs contain-
ing the chimeric E1, E2, or E1E2 proteins were recovered
after infection of the CHOE1, CHOE2, CHOE1E2 cell lines
with VSVDG*-G, respectively. In addition, the noncomple-
mented VSVDG* control virus was recovered from the
parent CHO cell line. The VSVDG*-G was also amplified
in CHO cells transfected with pCAG-VSVG. These viruses
were partially purified by centrifugation through 25% su-
crose and analyzed by immunoblotting. To determine the
infectious titer of the pseudotype VSVs, cells were in-
fected with the pseudotype viruses and incubated at
37°C for 16 h. Infectious units (IU) of virus in different cell
lines were determined by counting the number of GFP-
expressing cells by fluorescence microscopy.
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Serially diluted antibodies were incubated with 2.5 3
103 IU of the pseudotype VSV-E1E2 or VSVDG*-G for 30
in at 37°C. The amount of infectious virus remaining
nfectious titer was determined as described above by
ounting the number of GFP-expressing cells under flu-
rescence microscopy.
ffects of chemicals on infectivity of pseudotype
SVs
The pseudotype VSV-E1E2 or VSVDG*-G (2.5 3 103 IU)
was preincubated with various concentrations of bovine
lactoferrin or Suramin at 37°C for 60 min and inoculated
into HepG2 cells (4 3 104 cells) prepared in a 96-well
late. After absorption for 60 min at 37°C, the cells were
ashed with DMEM containing 10% FBS three times and
ncubated at 37°C for 16 h and IU were determined as
escribed above.
hemical modification of cells
HepG2 cells (4 3 104 cells) prepared in a 96-well plate
ere washed with serum-free DMEM three times and
ncubated with 25 ml of the serum-free DMEM containing
various concentration of Pronase, sodium periodate,
phospholipase C, and glycosaminoglycan lyases at 37°C
for 20, 60, 30, and 60 min, respectively. To stop the
treatment, an equal volume of DMEM containing 10%
FBS was inoculated. After washing with serum-free
DMEM once, the cells were infected with 2.5 3 103 IU of
he pseudotype VSV-E1E2 or VSVDG*-G and incubated at
7°C for 16 h and the number of the GFP positive cells
as determined.
eagents
Endo-b-N-acetylglucosaminidase H (Endo H), peptide-
-glycosidase F (PNGase F), and phospholipase C (Ba-
illus cereus Grade I) were obtained from Boehringer
annheim, Germany. Pronase and sodium periodate
NaIO4) were obtained from Aldrich, Tokyo, Japan. Hep-
aritinase (Flavobacterium heparinum), heparinase (F. he-
parinum), hyaluronidase (Streptomyces hyalurolyticus),
chondroitinase ABC (Proteus vulgaris), and keratanase
(Pseudomonas sp.) were kindly provided by Seikagaku
Corp., Tokyo, Japan. Anti-VSV polyclonal antibody was
purchased from Lee Biomolecular Research Laborato-
ries, Inc. (San Diego, CA). Bovine lactoferrin and Suramin
were obtained from Sigma Chemical Co.
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